Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Archives of Neurology

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHNEUR.62.10.1641-BPMID 16216954
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

  2005cited by this paper
• Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

  2005cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

  2000cited by this paper

• The PNKD gene is associated with Tourette Disorder or Tic disorder in a multiplex family

  2017cites this paper
• B Cells and Progressive Multifocal Leukoencephalopathy: Search for the Missing Link

  2015cites this paper
• The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

  2010cites this paper
• Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis

  2010cites this paper
• Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen

  2009cites this paper
• Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

  2009cites this paper
• B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

  2008cites this paper
• Identification and development of new therapeutics for multiple sclerosis.

  2008cites this paper
• Review: Innovative monoclonal antibody therapies in multiple sclerosis

  2008cites this paper
• The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies

  2008cites this paper
• Treating multiple sclerosis with monoclonal antibodies

  2008cites this paper
• Therapieentscheidungen bei Multipler Sklerose

  2008cites this paper
• [Choice of early and escalation treatment options for multiple sclerosis].

  2008cites this paper
• Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

  2007cites this paper
• How B Cells Contribute to Multiple Sclerosis Pathology

  2007cites this paper
• Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

  2007cites this paper
• Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).

  2007cites this paper
• Rationale for cytotoxic monoclonal antibodies in MS.

  2007cites this paper
• Review of Novel Immunotherapeutic Strategies for MS

  2007cites this paper
• B-cell targeting in rheumatoid arthritis and other autoimmune diseases

  2006cites this paper
• Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment.

  2006cites this paper